BioNtech Doses First Patient In Clinical Study Of Herpes Vaccine Candidate

Reuters (12/21, Chabba) reports, “BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine maker said on Wednesday.” T...